Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.
Cassava to stop trials of Alzheimer's drug after late-stage study failure
(Reuters) -Cassava Sciences said on Monday it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer plummeting more than 80% before the bell.
Cassava Sciences Stock Slides 84% as Alzheimer’s Trial Fails
Cassava Sciences stock collapsed after an Alzheimer’s drug the company was testing failed to significantly help participants in a clinical trial. The stock plummeted 84% to $4.15 Monday after reporting that a Phase 3 trial meant to demonstrate the efficacy of a medication called Simufilam fell short of key milestones.
Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's disease. Its drug failed the Phase 2 trial.
Cassava plummets 86% as simufilam phase 3 Alzheimer's trial misses endpoints
Cassava Sciences (NASDAQ:SAVA) stock has plummeted ~86% after announcing that Alzheimer's disease candidate simufilam did meet its co-primary endpoints in a phase 3 trial. Those endpoints were change in cognition and function from baseline to the end of week 52,
Alzheimer’s disease: toxic protein is turned bad by immune enzyme, mouse study shows
Tau behaves abnormally in the brain in people with Alzheimer’s disease. This latest study points to a reason why.
STAT18h
Roche’s TIGIT troubles continue, a novel Alzheimer’s target misses the mark, and other biotech news
I spent four crazy years writing about Cassava Sciences. Yesterday, the story ended exactly as I and many others knew it ...
Psychology Today4h
The Relationship Between Music and Alzheimer’s Disease
Alzheimer’s is the most common type of dementia. Music therapy can improve mood and cognitive performance in Alzheimer’s ...
FierceBiotech9h
Alector lays off 17% of staff after AbbVie-partnered Alzheimer's asset fails phase 2
Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...
Cassava shares sink on plans to stop Alzheimer's drug studies
(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...
BioSpace5h
Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II, Triggering a 17% Layoff
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
News Medical on MSN47m
Machine learning tool detects early signs of Alzheimer's in mice
Subtle signs of Alzheimer's disease can emerge decades before a diagnosis-;often in the form of irregular behaviors that reflect very early stages of brain dysfunction.
Cassava's Alzheimer's drug fails in late-stage study
(Reuters) -Cassava Sciences on Monday said its experimental Alzheimer's disease drug did not meet the main or secondary goals ...
GEN1h
Alzheimer’s Disease Neurodegeneration Held Back in Mice Treated Using Enzyme Inhibiting Nasal Spray
In mice, inhibiting protein S-palmitoylation Counteracted accumulation of harmful proteins in neurons and delayed onset and progression of cognitive decline.
The Daily Californian5h
Alzheimer’s Services of the East Bay to close in December
Alzheimer’s Services of the East Bay, or ASEB, will close its doors to the public Dec. 13.
‘We’re living in uncertainty’: My sister has Alzheimer’s disease. How do I know the right time to take control of her finances?
Dear Quentin,  I have two sisters who have developed Alzheimer’s disease. My younger sister is actually more severely ...